Please login to the form below
Zynquista
This page shows the latest Zynquista news and features for those working in and with pharma, biotech and healthcare.
FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes
It also turned down Lexicon Pharma and Sanofi’s SGLT2 inhibitor Zynquista (sotagliflozin) for this use in December, once again despite an earlier approval in Europe.
Latest news
-
FDA advisors say no to empagliflozin in type 1 diabetes
Earlier this year the panel was split on whether they should back approval of Lexicon Pharma’s Zynquista (sotagliflozin) as an insulin adjunct in these patients, and the FDA’s subsequent
-
Sanofi reveals positive phase 3 results for long-acting insulin Toujeo
The drug, Zynquista (sotagliflozin), was a key element in Sanofi’s plans to rebuild its diabetes franchise following the loss of patent protection for its basal insulin Lantus.
-
Sanofi exits Zynquista alliance with Lexicon
Regaining worldwide rights allows us to advance our efforts to realise the full value of the Zynquista programme as we prepare for regulatory filings in the US and in Europe in ... Zynquista was a key element in Sanofi’s plans to rebuild its diabetes
-
Sanofi sheds jobs in R&D restructuring
The FDA also recently rejected its Lexicon partnered SGLT1/SGLT2 inhibitor Zynquista.
-
J&J’s Invokana first SGLT2 to show kidney disease benefits
Meanwhile Sanofi and Lexicon's Zynquista and Eli Lilly and Boehringer Ingeheim's market leader Jardiance are also both in renal outcomes trials, with their respective results expected by 2022.
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
